The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 31, 2012
Filed:
Aug. 20, 2007
Daphne Winifred Bell, Arlington, MA (US);
Daniel A. Haber, Chestnut Hill, MA (US);
Pasi Antero Janne, Newton, MA (US);
Bruce E. Johnston, Brookline, MA (US);
Thomas J. Lynch, Newton, MA (US);
Matthew Meyerson, Concord, MA (US);
Juan Guillermo Paez, Boston, MA (US);
William R. Sellers, Chestnut Hill, MA (US);
Jeffrey E. Settleman, Newton, MA (US);
Raffaella Sordella, Bedford, MA (US);
Daphne Winifred Bell, Arlington, MA (US);
Daniel A. Haber, Chestnut Hill, MA (US);
Pasi Antero Janne, Newton, MA (US);
Bruce E. Johnston, Brookline, MA (US);
Thomas J. Lynch, Newton, MA (US);
Matthew Meyerson, Concord, MA (US);
Juan Guillermo Paez, Boston, MA (US);
William R. Sellers, Chestnut Hill, MA (US);
Jeffrey E. Settleman, Newton, MA (US);
Raffaella Sordella, Bedford, MA (US);
The General Hospital Corporation, Boston, MA (US);
Dana-Farber Cancer Institute, Inc., Boston, MA (US);
Abstract
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.